| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5384 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2793 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1688 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1356 | 2021 |
| Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1145 | 2021 |
| Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 491 | 2021 |
| Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 J Huo, A Le Bas, RR Ruza, HME Duyvesteyn, H Mikolajek, T Malinauskas, ... Nature structural & molecular biology 27 (9), 846-854, 2020 | 489 | 2020 |
| Neutralization of SARS-CoV-2 by destruction of the prefusion spike J Huo, Y Zhao, J Ren, D Zhou, HME Duyvesteyn, HM Ginn, L Carrique, ... Cell host & microbe 28 (3), 445-454. e6, 2020 | 372 | 2020 |
| Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays KR Bewley, NS Coombes, L Gagnon, L McInroy, N Baker, I Shaik, ... Nature protocols 16 (6), 3114-3140, 2021 | 243 | 2021 |
| Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity KA Ryan, KR Bewley, SA Fotheringham, GS Slack, P Brown, Y Hall, ... Nature communications 12 (1), 81, 2021 | 164 | 2021 |
| A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction M Ejemel, Q Li, S Hou, ZA Schiller, JA Tree, A Wallace, A Amcheslavsky, ... Nature communications 11 (1), 4198, 2020 | 151 | 2020 |
| Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19 FJ Salguero, AD White, GS Slack, SA Fotheringham, KR Bewley, ... Nature Communications 12 (1), 1260, 2021 | 127 | 2021 |
| Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations JA Tree, JE Turnbull, KR Buttigieg, MJ Elmore, N Coombes, J Hogwood, ... British Journal of Pharmacology 178 (3), 626-635, 2021 | 97 | 2021 |
| Synthetic heparan sulfate mimetic pixatimod (PG545) potently inhibits SARS-CoV-2 by disrupting the spike–ACE2 interaction SE Guimond, CJ Mycroft-West, NS Gandhi, JA Tree, TT Le, CM Spalluto, ... ACS central science 8 (5), 527-545, 2022 | 78 | 2022 |
| Upregulation of glucose uptake and hexokinase activity of primary human CD4+ T cells in response to infection with HIV-1 M Kavanagh Williamson, N Coombes, F Juszczak, M Athanasopoulos, ... Viruses 10 (3), 114, 2018 | 73 | 2018 |
| Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge KA Ryan, KR Bewley, SA Fotheringham, P Brown, Y Hall, AC Marriott, ... BioRxiv, 2020.05. 29.123810, 2020 | 42 | 2020 |
| mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P. 1 Brazilian variant H Parry, G Tut, R Bruton, S Faustini, C Stephens, P Saunders, C Bentley, ... Elife 10, e69375, 2021 | 24 | 2021 |
| BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P. 1 Brazilian variant HM Parry, G Tut, S Faustini, C Stephens, P Saunders, C Bentley, ... | 22 | 2021 |
| Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant KA Ryan, RJ Watson, KR Bewley, C Burton, O Carnell, BE Cavell, ... BioRxiv, 2021.12. 24.474081, 2021 | 17 | 2021 |
| Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variant KA Ryan, KR Bewley, RJ Watson, C Burton, O Carnell, BE Cavell, ... PLoS Pathogens 19 (4), e1011293, 2023 | 10 | 2023 |
